Back to search results

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Abroad (travel likely)RecruitingPHASE3

Conditions

Opioid Use Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Highland Hospital, Oakland, California, United States

    Contact: Study coordinator (Andrew Herring, MD) · aherring@alamedahealthsystem.org · 510-437-4800
    Contact: Principal Investigator (Andrew Herring, MD)

  • San Leandro Hospital, San Leandro, California, United States

    Contact: Study coordinator (Erik S Anderson, MD) · esanderson@alamedahealthsystem.org · 510-437-4970
    Contact: Principal Investigator (Erik Anderson, MD)

  • Maine Medical Center, Portland, Maine, United States

    Contact: Study coordinator (Tania Strout, PhD, RN, MS) · Tania.Strout@mainehealth.org
    Contact: Principal Investigator (Michael Baumann, MD)

  • Cooper University Hospital, Camden, New Jersey, United States

    Contact: Study coordinator (Christopher Jones, MD) · Jones-Christopher@CooperHealth.edu
    Contact: Principal Investigator (Christopher Jones)

  • University of Utah Hospital, Salt Lake City, Utah, United States

    Contact: Study coordinator (Alyrene Dorey, MD) · Alyrene.Dorey@hsc.utah.edu
    Contact: Principal Investigator (Alyrene Dorey, MD)
Study leads

  • Gail D'Onofrio, MD, MS

    Principal Investigator

    Yale University

  • Kathryn Hawk

    Principal Investigator

    Yale University

View source on ClinicalTrials.gov(opens in a new tab)